Pre-Made Efruxifermin Biosimilar, Fusion Protein targeting FGFR1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting BFGFR/CD331/CEK/ECCL/FGFBR/FGFR-1/FLG/FLT-2/FLT2/HBGFR/HH2/HRTFDS/KAL2/N-SAM/OGD/bFGF-R-1 for drug discovery and mechanism of action (MOA) research

Pre-Made Efruxifermin Biosimilar, Fusion Protein targeting FGFR1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting BFGFR/CD331/CEK/ECCL/FGFBR/FGFR-1/FLG/FLT-2/FLT2/HBGFR/HH2/HRTFDS/KAL2/N-SAM/OGD/bFGF-R-1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efruxifermin is a differentiated Fc-FGF21 fusion protein designed to mimic the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes. Efruxifermin is a fusion protein of human IgG1 Fc domain linked to a modified human FGF21 (Fc-FGF21) with balanced in vitro agonist potency at FGFR1c, FGFR2c and FGFR3c. FGF21 is a key regulator of whole-body and individual organ metabolism. It activates a cell membrane co-receptor complex of ¦Â-klotho and one of its cognate FGF receptors (FGFRs), FGFR1c, FGFR2c or FGFR3c. FGF21 and its analogs improve metabolic status in preclinical models of obesity, diabetes and NASH. Efruxifermin is longer acting than most FGF21 analogs, with a 3¨C3.5-d half-life.